Search Results

🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

scientific publications, he is most beloved as a mentor and his relentless encouragement that shaped the careers

In 2013, Demet began her independent research career at the University of Chicago within the Department receptor activator and continuously work to identify novel chemical modulators of AGPCRs through assay development I have previous work experience at two separate contract research organizations centered on assay development

His thesis work led to the development and application of light energy transfer methodology to study His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signaling mechanisms in development, adult tissue homeostasis, His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway biotech companies, ModMab Therapeutics , and AntlerA Therapeutics , which are pursuing the clinical development

Discover how Celtarys Research is transforming GPCR assay development with fluorescent ligands in this At Celtarys, the focus is on enabling fast, customizable development of fluorescent ligands and chemical Their approach is highly consultative—they don’t just sell ligands, they co-develop solutions. Whether you're designing assays, developing probes, or seeking better tools for GPCR drug discovery, , GPCR assay development , G protein-coupled receptors , GPCR podcast , Celtarys partnership Summary

At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development

The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers Cardarelli is a drug development leader with extensive experience driving drug discovery teams in bringing biology, pharmacology, translational medicine, oncology, immuno-oncology, immunology, and clinical development While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic development

aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

led me to the Ottawa Hospital Research Institute (then the Moses and Rose Loeb Research Institute) to develop We are also currently developing the translational component of our research to capitalize on the druggability We hope our research will aid in the development of new therapeutic interventions for the alleviation

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Gebhard Schertler, he developed methods for kinetic mathematical analysis of GPCR signaling. Before focusing on the development of innovative mathematical modeling and simulation methods for drug Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery of interdisciplinary teamwork in drug and technology development, noting the challenges of communication

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools Her work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology Custom Development Customized fluorescent ligands developed in less than 3 months with optimal properties Custom Development Tailored fluorescent probes designed for unique research requirements.

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Centre that is developing particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development

Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA

Department, Ken Vecchio helping set the foundation for the Nanoengineering Materials Research Center and developing Scientists and Engineers working at the nanoscale, specifically protein engineering and small molecule drug development

Khorana’s lab made early key contributions and developed strategies to express, reconstitute and assay He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay Tom’s lab also developed an amber codon suppression method to genetically encode unnatural amino acids Early applications included “targeted photo-crosslinking,” and more recently, the parallel development

Sampedro-Castaneda, Marisol1, Claxton, Suzanne1, Skehel, Mark2, Ultanir, Sila K.1 1Kinases and Brain Development Mihaylov " I am a postdoctoral researcher in the kinases and brain development laboratory led by Dr Sila moved to King's College London, where my interest and passion for kinases in brain health and disease developed I have recently also developed a strong interest in adhesion GPCRs and in particular, Bai1. " Simeon

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

Podcast , leaders from academia and biotech unpack what effective collaboration really looks like when developing The episode explores gpcr internalization , fluorescence-based probe design, and how functional assay development Listen This episode is for scientists and leaders who are: Navigating the transition from academic tool development co-founding the company in 2021, she has led all scientific activities, from proprietary technology development His research focuses on bottom-up chemical tool development for imaging and interrogating GPCRs and other

completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

His team develops fluorescence-based and chemically engineered tools to study gpcr internalization and engagement in intact islets and neuronal circuits — insights that inform next-generation functional assay development His group develops imaging and chemical biology tools to reveal how GLP-1 and GIP receptors operate within

This was followed by a postdoctoral role at the Polytechnic University of Turin (Italy), where he developed Now in a tenure-track position, his research spans the development of computational methods such as structure-based